Published online Aug 28, 2022. doi: 10.4329/wjr.v14.i8.311
Peer-review started: April 11, 2022
First decision: May 30, 2022
Revised: May 30, 2022
Accepted: August 5, 2022
Article in press: August 5, 2022
Published online: August 28, 2022
The aim of this study was to define clinical evidence supporting that triple rule-out computed tomography angiography (TRO CTA) is a comprehensive and feasible diagnostic tool in patients with novel coronavirus disease 2019 (COVID-19) who were admitted to the emergency department for acute chest pain. Optimizing diagnostic imaging strategies in COVID-19 related thromboembolic events, will help for rapid and noninvasive diagnoses and results will be effective for patients and healthcare systems in all aspects.
Acute chest pain in COVID 19 patients becomes more difficult due to increasing differential diagnosis. TRO CTA helps diagnosis by excluding pulmonary thromboembolism (PTE), coronary artery disease, and acute aortic syndrome at the same time.
To decrease the morbidity and mortality rates in patients.
Our study is a retrospective study.
No pathology was detected in 31 of 57 patients included in the study. PTE was detected in 11 patients. The diabetes mellitus rate was much higher in the acute coronary syndrome group, particularly in the PTE group. The rate of dyslipidemia was significantly higher in the group with pathology on CTA while compared to those without pathology apart from imaging findings of the pneumonia group
TRO CTA can be a useful method in the differential diagnosis of COVID-19 patients who present to the emergency department with chest pain.
The use of TRO CTA will reduce mortality and morbidity as it will accelerate the diagnosis and treatment process in the future. Studies will proceed in this direction.